Organisation paid for research Program year 2021 Source: CMS Open Payments

Allergy Asthma and Sinus Center, SC

Neither a doctor nor a teaching hospital

Research payments

$148,705

19 payments

Through program year 2021, Allergy Asthma and Sinus Center, SC is reported as receiving $148,705 in research payments, across 19 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2021	Research	$37,043	2
2020	Research	$40,858	12
2019	Research	$70,804	5

Breakdown

Who paid Research payments · program years 2019–2021

AstraZeneca Pharmaceuticals LP $134,925 12 payments
Sanofi US Services Inc. $13,781 7 payments

Studies the money was for Research payments · program years 2019–2021

A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma $51,820 4 payments
The CHRONICLE Study is a multi center non interventional prospective cohort study of adults with severe asthma who do not achieve control with high dose inhaled corticosteroid ICS therapy with additional controllers and or require systemic corticosteroid or monoclonal antibody therapy $42,974 5 payments
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma $23,865 1 payment
Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos) $16,267 2 payments
Efficacy and safety of SAR440340/REGN3550, dupilumab and the concurrent administration of both in the treatment of patiens with moderate to severe Chronic Obrstructive Pulmnonary Disease (COPD) and sy $11,079 2 payments
A Randomized Double Blind, 52 Week placebo Controlled Efficacy & Safety Study of Dupilumab in Patients with Bilateral nasal polyposis treted with intranasal corticosteriods $1,152 1 payment
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 12-week Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety, and Tolerability of SAR440340 and the Coadministration of SAR440340 $783 1 payment
A Randomized double blind placebo controlled parallel goup 12 week proof of concept study to assess the efficacy, safety, and tolerability of SAR440340 and the coadministration of SAR440340 and dupilu $564 2 payments
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of SAR440340, in Patients With Moderate-to-severe Chronic O $203 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.